Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
5.27
-0.15 (-2.68%)
Apr 21, 2026, 11:25 AM EDT - Market open
Compass Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
39
Market Cap
949.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 850.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.72B |
| Maravai LifeSciences Holdings | 185.74M |
| Geron | 183.88M |
| Xencor | 125.58M |
| MeiraGTx Holdings | 81.39M |
| Evommune | 13.00M |
| Janux Therapeutics | 10.00M |
CMPX News
- 6 weeks ago - Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Compass Therapeutics Provides Corporate Update - GlobeNewsWire
- 3 months ago - Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Compass Therapeutics Announces Key Leadership Appointments - GlobeNewsWire
- 4 months ago - Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 5 months ago - Compass Therapeutics to Participate in Upcoming December Investor Events - GlobeNewsWire
- 5 months ago - Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire